Alpha7beta1 Integrin Modulatory Agents for Muscular Dystrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for muscular dystrophies such as Duchenne muscular dystrophy, Fukuyama congenital muscular dystrophy, and merosin deficient congenital muscular dystrophy type 1A lack effective solutions for improving muscle regeneration and maintaining muscle function, as they primarily focus on symptom management rather than addressing the underlying muscle degeneration.
Innovation Solution
Administration of α7β1 integrin modulatory agents like ciclopirox ethanolamine, deferoxamine, 2,2-dipyridyl, 5α-cholestan-3β-ol-6-one, and specific compounds (e.g., Compound ID#1001, Compound ID#1002, Compound ID#1003) to increase α7β1 integrin expression or activity, enhancing muscle regeneration, repair, and maintenance in subjects with muscular dystrophy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for muscular dystrophy focus on symptom management, then clinical symptoms can be temporarily alleviated, but the underlying muscle degeneration continues to progress
Solution Approach 1:
The patent applies preliminary action by administering α7β1 integrin modulatory agents before significant muscle degeneration occurs. The treatment aims to prevent or slow the progression of muscular dystrophy by modulating integrin expression early in the disease course, rather than merely managing symptoms after damage has already occurred. This proactive approach seeks to maintain muscle function and structure before irreversible degeneration sets in.
2Productivity
If α7β1 integrin modulatory agents are administered to increase integrin expression, then muscle regeneration and maintenance are enhanced, but the complexity of treatment protocols increases
Solution Approach 1:
The patent applies parameter changes by modifying the expression levels of α7β1 integrin through pharmacological agents. By changing the biochemical parameter of integrin expression in muscle cells, the treatment enhances muscle regeneration and maintenance capabilities. The modulatory agents alter the physiological state of muscle tissue at the molecular level, promoting healthier muscle function and structure in dystrophic conditions.
3Duration of action of stationary object
If comprehensive muscle regeneration therapy is implemented, then long-term muscle function is improved, but the cost and accessibility of treatment decreases
Solution Approach 1:
The patent uses α7β1 integrin modulatory agents as intermediaries to bridge the gap between current limited treatments and ideal muscle regeneration outcomes. These pharmacological compounds serve as mediators that can be administered systemically to achieve widespread effects on muscle tissue. By using small molecule drugs rather than complex cellular therapies, the approach aims to improve long-term muscle function while maintaining relative ease of manufacturing and potential accessibility.
Data Source
AI summary
Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.